Intraperitoneal Therapy for Peritoneal Cancer

Abstract

Cancers originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and liver) account for approximately 250,000 new cancer cases annually in the USA. Peritoneal metastases are common owing to locoregional spread and distant metastases of extraperitoneal cancers. A logical treatment is intraperitoneal therapy, as multiple studies have shown significant targeting advantage for this treatment, including significant survival benefits in stage III, surgically debulked ovarian cancer patients. However, the clinical use of intraperitoneal therapy has been limited, in part, by toxicity, owing to the use of indwelling catheters or high drug exposure, by inadequate drug penetration into bulky tumors (>1 cm) and by the lack of products specifically designed and approved for intraperitoneal treatments. This article provides an overview on the background of peritoneal metastasis, clinical research on intraperitoneal therapy, the pharmacokinetic basis of drug delivery in intraperitoneal therapy and our development of drug-loaded tumor-penetrating microparticles.

Colloidal stability of nano-sized particles in the peritoneal fluid: Towards optimizing drug delivery systems for intraperitoneal therapy

“…All these are still major challenges in IP delivery systems [22]. The data presented in this study undoubtedly propose rapid aggregation of positively and negatively charged nanoparticles in the peritoneal fluids.…”

“…In the past few years, different DDSs were evaluated for IP administration [21,22], Among them are targeted nanocarriers [23], nanoparticles for intraperitoneal gene delivery [24], micelles [25], microparticle [26,27] and hydrogels for sustained release in the peritoneal cavity [28][29][30].…”

IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment

“…11 IL-33 is a short-lived, locally active cytokine. We hypothesized that peritoneal immunotherapy using IL-33 could impact peritoneally-metastasized ovarian cancer by activating tumor-associated inflammation.…”

Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?

“…Numerous attempts have been made to deliver chemotherapeutics into tumors confined to the peritoneal cavity using NPs ( Figure 4A), via both IV and IP routes [47][48][49]. We have also recently reviewed different non-viral nucleic acid delivery systems that were IP administered for the treatment of peritoneal cancer [50].…”